Hong Kong SAR

A year ago, Hong Kong’s stock exchange (HKEX) added a new chapter to its regulations, allowing pre-revenue biotechnology companies to list. The historic move has turned the city into the biotech IPO hub of Asia. But its fortune could change if the Mainland’s new Nasdaq-style Shanghai tech board, which offers similar pre-revenue concessions, stems the flow of its primarily Chinese issuers.

Semiconductor Manufacturing International Corporation (SMIC), a Shanghai-based chipmaker, returned to the Panda market on Monday with two 180-day notes, raising Rmb1.5bn ($223m) in total.

Duiba Group has completed its second attempt at listing on the Hong Kong Stock Exchange.

Boutique investment bank Alantra has made new hires across its offices in Europe, Asia and the US.

Chinese software company Duiba Group will complete its Hong Kong IPO after local markets close on Monday with bookrunners indicating a final price in the lower half of the guidance range.

China’s Ascentage Pharma Group International has refiled a prospectus for its second attempt to list on the Hong Kong Stock Exchange (HKEX).

There are many inaccurate pejorative stereotypes about investment bankers, but one I’ll gladly admit is true is that we are a snobbish bunch when it comes to travel.

CLSA named Richard Gould as its new chief executive on Tuesday alongside three other senior appointments, a month after losing former CEO Jonathan Slone.

Viva Biotech Holdings has kicked off bookbuilding for its Hong Kong listing, eyeing proceeds of up to HK$1.52bn ($194m). The firm has secured the support of Chinese state-owned giant Sinopharm.

SEG Automotive, a starter motor manufacturer, is tapping the offshore loan market for a €300m dual tranche facility.

Chinese software firm Duiba Group covered the book for its up to HK$900m ($114.7m) IPO on Tuesday morning, just hours after launch, according to a source close to the deal.

Melco, the casino operator, played its US investor cards on Wednesday to build a $500m bond sale.